Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.46 USD | -0.12% | +0.40% | -19.20% |
May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.20% | 81.73B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Wells Fargo Adjusts Gilead Sciences' Price Target to $74 from $63, Maintains Equalweight Rating